View Older Stories View More Recent Stories
-
Ionis Pharmaceuticals (IONS) PT Raised to $95 at Morgan Stanley
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) Misses Q4 EPS by 8c, provides guidance
-
BIOGEN publishes study results for high-dose nusinersen in Nature Medicine
-
DAWNZERA gets European Commission approval for hereditary angioedema
-
BIOGEN receives EU approval for high dose SPINRAZA for spinal muscular atrophy
-
Ionis Pharmaceuticals (IONS) PT Raised to $95 at RBC Capital
-
TD Cowen on Ionis Pharmaceuticals (IONS): 'New Launches And Key Pipeline Catalysts To Drive Upside'
-
Biogen (BIIB): High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
-
Ionis' DAWNZERA receives EU regulatory committee recommendation for HAE
-
Ionis prices $700 million convertible notes to refinance 2026 debt
-
Ionis announces $700 million convertible notes offering to refinance 2026 debt
-
Bernstein on Ionis Pharmaceuticals (IONS): 'Very Positive Doc Call on SHTG Data'
-
Ionis reports olezarsen cut triglyceride levels up to 72% in pivotal trials
-
Ionis presents long-term DAWNZERA data at ACAAI meeting
-
Ionis Pharmaceuticals (IONS) PT Raised to $99 at TD Cowen, Top Pick
-
Ionis Pharmaceuticals (IONS) PT Raised to $72 at Leerink Partners
-
Ionis Pharmaceuticals (IONS) Tops Q3 EPS by 42c, Beats on Revenue; Offers FY25 EPS Guidance
-
Bernstein's US Biotech 3Q25 Preview: 'Expect Beats from ALNY and REGN'
-
TD Cowen on Ionis Pharmaceuticals (IONS): 'Deep Cardio & Neuro Pipelines Set Up Continued Revs Growth'
-
Ionis Pharmaceuticals (IONS) PT Raised to $85 at Raymond James
-
Ionis (IONS) Hold rating reiterated at Stifel after Innovation Day presentation
-
Ionis Pharmaceuticals (IONS) PT Raised to $90 at Oppenheimer
-
JPMorgan Upgrades Ionis Pharmaceuticals (IONS) to Overweight
-
Ionis hosts innovation day, targets sustained cash flow by 2028
-
Ionis Pharmaceuticals (IONS) PT Raised to $67 at Stifel
-
Goldman Sachs Upgrades Ionis Pharmaceuticals (IONS) to Neutral
-
Ionis Pharmaceuticals (IONS) PT Raised to $68 at Leerink Partners
-
FDA requests technical updates for Biogen's high dose nusinersen application
-
Ionis Pharmaceuticals (IONS) PT Raised to $92 at Guggenheim
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) PT Raised to $83 at BofA Securities
-
Ionis reports positive results for Alexander disease drug zilganersen
-
Ionis Pharmaceuticals (IONS) Halted, News Pending
-
H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
-
TRYNGOLZA approved in Europe for rare genetic syndrome FCS
-
Ionis expands adaptive event for neurological disease communities
-
Ionis Pharmaceuticals (IONS) PT Raised to $80 at RBC Capital
-
Ionis Pharmaceuticals (IONS) PT Raised at Bernstein Following 'Positive Topline Results'
-
Ionis Pharmaceuticals (IONS) PT Raised to $95 at H.C. Wainwright
-
BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform
-
Ionis Pharmaceuticals (IONS) spreader of 5K contracts of September 55 calls and puts as share price up 35%
-
Ionis Pharmaceuticals (IONS) PT Raised to $81 at Oppenheimer
-
Stifel Reiterates Ionis Pharmaceuticals (IONS) at Hold, 'a highly-positive outcome for IONS'
-
Ionis olezarsen shows 72% triglyceride reduction in Phase 3 studies
-
Ionis Pharmaceuticals (IONS) PT Raised at Piper Sandler Following FDA Approval
-
Ionis Pharmaceuticals (IONS) PT Raised to $70 at H.C. Wainwright
-
Ionis Pharmaceuticals (IONS) PT Raised to $82 at Wells Fargo
-
Ionis Pharmaceuticals (IONS) PT Raised to $69 at Citi
-
Ionis Pharmaceuticals (IONS) PT Raised to $64 at BofA Securities
